Barilani Mario, Peli Valeria, Manzini Paolo, Pistoni Clelia, Rusconi Francesco, Pinatel Eva Maria, Pischiutta Francesca, Tace Dorian, Iachini Maria Chiara, Elia Noemi, Tribuzio Francesca, Banfi Federica, Sessa Alessandro, Cherubini Alessandro, Dolo Vincenza, Bollati Valentina, Fiandra Luisa, Longhi Elena, Zanier Elisa R, Lazzari Lorenza
Unit of Cell and Gene Therapies, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Department of Medical Oncology and Hematology, University Hospital Zurich, Switzerland.
Int J Biol Sci. 2024 Nov 22;20(15):6255-6278. doi: 10.7150/ijbs.100113. eCollection 2024.
Extracellular vesicles (EV) have emerged as promising cell-free therapeutics in regenerative medicine. However, translating primary cell line-derived EV to clinical applications requires large-scale manufacturing and several challenges, such as replicative senescence, donor heterogeneity, and genetic instability. To address these limitations, we used a reprogramming approach to generate human induced pluripotent stem cells (hiPSC) from the young source of cord blood mesenchymal stem/stromal cells (CBMSC). Capitalizing on their inexhaustible supply potential, hiPSC offer an attractive EV reservoir. Our approach encompassed an exhaustive characterization of hiPSC-EV, aligning with the rigorous MISEV2023 guidelines. Analyses demonstrated physical features compatible with small EV (sEV) and established their identity and purity. Moreover, the sEV-shuttled non-coding (nc) RNA landscape, focusing on the microRNA and circular RNA cargo, completed the molecular signature. The kinetics of the hiPSC-sEV release and cell internalization assays unveiled robust EV production and consistent uptake by human neurons. Furthermore, hiPSC-sEV demonstrated cell tissue-protective properties. Finally, via bioinformatics, the potential involvement of the ncRNA cargo in the hiPSC-sEV biological effects was explored. This study significantly advances the understanding of pluripotent stem cell-derived EV. We propose cord blood MSC-derived hiPSC as a promising source for potentially therapeutic sEV.
细胞外囊泡(EV)已成为再生医学中颇具前景的无细胞疗法。然而,将原代细胞系来源的EV转化为临床应用需要大规模生产,并且存在一些挑战,如复制性衰老、供体异质性和基因不稳定性。为了解决这些局限性,我们采用重编程方法,从年轻的脐带血间充质干/基质细胞(CBMSC)来源生成人类诱导多能干细胞(hiPSC)。利用其无穷的供应潜力,hiPSC提供了一个有吸引力的EV库。我们的方法包括对hiPSC-EV进行详尽的表征,符合严格的MISEV2023指南。分析表明其物理特征与小EV(sEV)相符,并确定了它们的身份和纯度。此外,聚焦于微小RNA和环状RNA货物的sEV穿梭非编码(nc)RNA图谱,完善了分子特征。hiPSC-sEV释放动力学和细胞内化试验揭示了强大的EV产生以及人类神经元对其的持续摄取。此外,hiPSC-sEV表现出细胞组织保护特性。最后,通过生物信息学,探索了ncRNA货物在hiPSC-sEV生物学效应中的潜在作用。这项研究显著推进了对多能干细胞来源的EV的理解。我们提出脐带血间充质干细胞来源的hiPSC作为潜在治疗性sEV的一个有前景的来源。